Abstract
Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It isnot known whether theamount or the distribution of other types of fat is associated with survival after coloncancer. Methods: We prospectively examined postdiagnostic total, animal, and vegetable fats, as well as the saturated, monounsaturated, polyunsaturated, and trans fat in relation to disease-free survival among 1,011 patients with stage III colon cancer. Patients were enrolled between 1999 and 2001 at the onset of adjuvant chemotherapy and followed for recurrence or death through 2009. Results: During median follow-up of 7 years, we observed 305 deaths and 81 recurrences (total events: 386). Neither total nor any specific type of dietary fat examined was statistically significantly associated with risk of cancer recurrence or death from any cause (disease-free survival) after stage III colon cancer. Conclusions: The amount and type (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer does not appear to be substantially associated with risk of recurrence or survival. Impact: Neither total nor major types (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer was associated with cancer recurrence or survival.
Original language | English (US) |
---|---|
Pages (from-to) | 1227-1230 |
Number of pages | 4 |
Journal | Cancer Epidemiology Biomarkers and Prevention |
Volume | 27 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2018 |
Funding
Research reported in this publication was supported by the NCI of NIH under award numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology; D. Niedzwiecki and F. Ou), U10CA138561 (to A.P. Venook), U10CA180791 (to L. Saltz), U10CA180820 (to A. Benson), U10CA180867 (to J.A. Meyerhardt, S. Zhang, R. Mayer, and S. Ogino), U10CA180888 (to A. Hantel), UG1CA189858 (to J.N. Atkins), K07CA197077 (to E.L. Van Blarigan), R01CA118553 (to C.S. Fuchs and D. Niedzwiecki), R01CA149222 (to J.A. Meyerhardt and D. Niedzwiecki), P50CA127003 (to C.S. Fuchs and J.A. Meyerhardt), R35CA197735 (to S. Ogino), and K99CA215314 (to M. Song). Dr. Song also received support from the American Cancer Society (MRSG-17-220-01-NEC) and American Association for Cancer Research (17-40-12-SONG), and this research was supported in part by funds from Pharmacia & Upjohn Company (now Pfizer Oncology; to C. Fuchs). Finally, this research was supported in part by a Stand Up To Cancer Colorectal Cancer Dream Team Translational Research Grant (to C.S. Fuchs, grant number: SU2C-AACR-DT22-17). Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C.
ASJC Scopus subject areas
- General Medicine